Sanofi SAN 1.00% agreed to buy Blueprint Medicines BPMC -0.15% for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC ...

France-headquartered pharmaceutical giant Sanofi announced on Monday its intention to acquire Blueprint Medicines Corporation, a US-based biopharmace Tuesday, 02 January 2024 12:17 GMT عربي ...

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.

Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.

Sanofi acquires Blueprint Medicines for $9.1 billion, gaining Ayvakit, a rare disease treatment approved in the US and EU for multiple conditions.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi SAN -1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Blueprint’s CEO, Kate Haviland, expressed pride in the company’s innovations and collaborations that have improved patient outcomes. She anticipates that the merger with Sanofi will accelerate their ...

The French pharmaceutical giant struck a deal to buy the Cambridge biotech for about $9.1 billion, or $129 per share. Blueprint’s (Nasdaq: BPMC) shares began trading at $103.17 apiece on Monday ...

The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.